Royalty Pharma (RPRX) Acquisitions (2025)
Royalty Pharma (RPRX) posted Acquisitions of $226000.0 for Q3 2025.
Powered by 
Analysis
Royalty Pharma (RPRX) Acquisitions (2025) Analysis & Trends
Royalty Pharma has reported Acquisitions for 1 years, with the latest figure at $226000.0 in Q3 2025.
- Quarterly Acquisitions changed N/A year-over-year to $226000.0 in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $226000.0 (changed N/A YoY) and the FY2025 annual result came in at $74.4 million, changed N/A from the prior year.
- Acquisitions steadied at $226000.0 in Q3 2025 per RPRX's latest filing.
- Over five years, Acquisitions peaked at $226000.0 in Q3 2025 and troughed at $226000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | - |